Skip to content
Trending storyWatching

Standard kidney function tests underestimate chronic kidney disease in cancer patients

1 report1 sourceupdated 2 days ago

Start here

Synthesis

At ASN Kidney Week 2026, a University of São Paulo Medical School team reported that routine kidney function tests substantially underestimate chronic kidney disease in people with cancer. Among 1,200 patients with solid tumors, CKD prevalence was 18.9% based on measured GFR, compared with 10.2% using creatinine-based estimation and 15.7% with combined creatinine and cystatin C estimation. In patients whose measured GFR fell between 45 and 59, 72.1% were misclassified as normal by creatinine-based testing; adding cystatin C improved accuracy, but concordance with measured GFR remained poor. Using cisplatin as an example, the researchers warned that estimation errors can lead to inadequate dose adjustments and increased toxicity risk. Whether clinical practice guidelines will revise how kidney function is assessed in oncology remains an open question.

Written by a model from the reports · updated 1 day ago

Coverage timeline

Follow the coverage to see the different angles.

Oct 24
  1. medicalxpress.comPick
    Standard kidney function tests underestimate chronic kidney disease in people with cancer

    At ASN Kidney Week 2026, a University of São Paulo Medical School team compared measured GFR (mGFR) with creatinine- and cystatin-C-based estimates in 1,200 patients with solid tumors. CKD prevalence was 18.9% by mGFR, 10.2% by creatinine-based estimate, and 15.7% by the combined estimate. Among patients with mGFR of 45-59, 72.1% were classified as normal by creatinine-based estimation; adding cystatin C improved results but concordance remained poor. Using cisplatin as an example, the authors note that GFR estimation errors may lead to inadequate anticancer drug dose adjustments and increased toxicity risk.

Heat trend for this story

Heat now 3·Peak in the comparable set 10 (Oct 24 03:00)·Change over 24h in the comparable set -50%·Participants now 1

Participants counted1
00.250.50.751
Heat over time
02.557.510Oct24Oct24Oct25Oct25

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org